Neoplasms, Germ Cell and Embryonal: Clinical Trials

8793 trials for Neoplasms, Germ Cell and Embryonal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3976 completed, 1274 recruiting, 1091 terminated, 967 unknown. 3521 Phase 2, 2871 Phase 1, 1054 Not applicable, 531 Phase 3, 254 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23521Completed 1628, Terminated 542, Recruiting 437, Unknown 335, Active not recruiting 295, Withdrawn 152, Not yet recruiting 101, Suspended 21, Enrolling by invitation 10
Phase 12871Completed 1361, Terminated 475, Recruiting 385, Active not recruiting 240, Unknown 200, Withdrawn 110, Not yet recruiting 68, Suspended 23, Enrolling by invitation 9
Not applicable1054Completed 433, Recruiting 224, Unknown 146, Active not recruiting 64, Terminated 64, Not yet recruiting 61, Withdrawn 47, Suspended 10, Enrolling by invitation 5
Phase 3531Completed 242, Recruiting 75, Unknown 72, Active not recruiting 56, Terminated 52, Not yet recruiting 17, Withdrawn 16, Suspended 1
Early Phase 1254Completed 77, Recruiting 50, Terminated 40, Active not recruiting 27, Unknown 27, Not yet recruiting 17, Withdrawn 15, Suspended 1
Phase 476Completed 27, Unknown 14, Recruiting 10, Not yet recruiting 8, Terminated 6, Active not recruiting 5, Withdrawn 5, Enrolling by invitation 1

Follow this condition Literature Review of Neoplasms, Germ Cell and Embryonal trials Research Report on Neoplasms, Germ Cell and Embryonal

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas
RNS System Implantation - Glioma, Glioma Intracranial
Not applicableNot yet recruitingMedical College of Wisconsin32028-08-012026-10-13
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma
Not applicableNot yet recruitingJonsson Comprehensive Cancer Center1002027-09-022026-10-19
Residual IDH1-Mutant Tumor Cell Quantification Study
UR-ddPCR - Glioma
Not applicableNot yet recruitingNYU Langone Health1052027-08-012026-09-29
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-08-27
Combination Immunotherapy Targeting Melanoma
Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-08-27
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)762027-06-252026-10-16
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)
Phase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhD972027-06-012026-09-15
DLL3 CAR-T Therapy Targeting Brain Tumors
4SCAR DLL3 T cells - Glioblastoma of Cerebellum
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-09-01
Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma
Temozolomide (TMZ) - Cutaneous Melanoma
Phase 2Not yet recruitingAssistance Publique Hopitaux De Marseille282027-06-012026-09-08
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma
Phase 1 / Phase 2Not yet recruitingUniversity of Nebraska412027-06-012026-10-05
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Phase 2RecruitingChildren's Oncology Group512027-05-152026-09-24
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma
Phase 2Not yet recruitingNorthwestern University562027-05-052026-10-07
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
[F-18]MeFAMP PET - Healthy Volunteers, Recurrent Glioma
Early Phase 1Not yet recruitingUniversity of Alabama at Birmingham282027-04-012026-08-20
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype
Phase 2 / Phase 3Not yet recruitingEverfront Biotech Co., Ltd.1752027-04-012026-09-10
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma
Phase 2Not yet recruitingRapa Therapeutics LLC652027-03-012026-03-19
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 2Not yet recruitingNationwide Children's Hospital122027-03-012026-09-09
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2
Phase 3Not yet recruitingNuvation Bio Inc.1402027-03-012026-07-17
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center362027-03-012026-10-01
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
Safusidenib - Glioma : Oligodendroglioma or Astrocytoma
Phase 2Not yet recruitingUniversity of Zurich202027-03-012026-09-21

Showing 20 of 8793. Sign in to see all of them.

Narrower conditions

Melanoma (3197)  ·  Glioblastoma (2067)  ·  Glioma (1446)  ·  Brain Neoplasms (1010)  ·  Astrocytoma (676)  ·  Neoplasms (665)  ·  Neuroblastoma (652)  ·  Neuroendocrine Tumors (538)  ·  Carcinoma, Non-Small-Cell Lung (502)  ·  Gliosarcoma (487)  ·  Central Nervous System Neoplasms (472)  ·  Breast Neoplasms (432)  ·  Oligodendroglioma (410)  ·  Neoplasm Metastasis (400)  ·  Sarcoma (399)

Broader conditions

Neoplasms by Histologic Type (8765)  ·  Neuroectodermal Tumors (8492)  ·  Neoplasms, Nerve Tissue (8474)  ·  Neoplasms (8128)  ·  Neoplasms by Site (5498)  ·  Neoplasms, Glandular and Epithelial (5210)  ·  Neoplasms, Neuroepithelial (4108)  ·  Neuroendocrine Tumors (3993)  ·  Skin and Connective Tissue Diseases (3390)  ·  Skin Diseases (3372)  ·  Nevi and Melanomas (3367)  ·  Skin Neoplasms (3001)  ·  Glioma (1879)  ·  Nervous System Diseases (1746)

Interventions

Temozolomide (671)  ·  pembrolizumab (393)  ·  Radiotherapy (391)  ·  Nivolumab (370)  ·  Cyclophosphamide (327)  ·  Ipilimumab (303)  ·  Bevacizumab (279)  ·  Carboplatin (223)  ·  Magnetic Resonance Spectroscopy (215)  ·  Etoposide (187)  ·  Cisplatin (172)  ·  aldesleukin (169)  ·  Radiation (140)  ·  Filgrastim (131)  ·  Interleukin-2 (130)

Sponsors

National Cancer Institute (NCI) (561)  ·  M.D. Anderson Cancer Center (219)  ·  Memorial Sloan Kettering Cancer Center (190)  ·  Children's Oncology Group (118)  ·  Novartis Pharmaceuticals (107)  ·  Bristol-Myers Squibb (92)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (91)  ·  Mayo Clinic (87)  ·  Duke University (85)  ·  Dana-Farber Cancer Institute (73)  ·  H. Lee Moffitt Cancer Center and Research Institute (65)  ·  Hoffmann-La Roche (62)  ·  Jonsson Comprehensive Cancer Center (60)  ·  St. Jude Children's Research Hospital (60)  ·  European Organisation for Research and Treatment of Cancer - EORTC (58)

Countries

United States (5132)  ·  France (863)  ·  Canada (655)  ·  China (636)  ·  Germany (594)  ·  Italy (573)  ·  United Kingdom (570)  ·  Spain (536)  ·  Australia (517)  ·  Netherlands (433)  ·  Switzerland (342)  ·  Belgium (309)  ·  Austria (196)  ·  South Korea (192)  ·  Denmark (190)

Top investigators

Steven A Rosenberg, M.D. (31)  ·  Steven A. Rosenberg, MD, PhD (27)  ·  Stanislaw R. Burzynski, MD, PhD (19)  ·  Annick Desjardins, MD, FRCPC (16)  ·  Nader Sanai, MD (16)

Results publications

PMID 31401903, PMID 36648215, PMID 25667295, PMID 24983357, PMID 39504507, PMID 22555974, PMID 23633099, PMID 34171339, PMID 34266694, PMID 37934000, PMID 38335473, PMID 19269895, PMID 22256804, PMID 25649350, PMID 26446943, PMID 31395089, PMID 32691060, PMID 32746839, PMID 36346112, PMID 38968568, PMID 39777725, PMID 15758009, PMID 23457002, PMID 23545055, PMID 23861247, PMID 24408395, PMID 24552317, PMID 24577748, PMID 25098701, PMID 25113840, PMID 27864013, PMID 29023494, PMID 29982805, PMID 30202085, PMID 30736858, PMID 32305010, PMID 32747469, PMID 33360855, PMID 34081125, PMID 34225229, PMID 34331515, PMID 34754076, PMID 35468680, PMID 36653848, PMID 37072349, PMID 37142373, PMID 37540556, PMID 39462179, PMID 39500789, PMID 40341199

NIH funding

2023 (67), U10CA098543 (51), U10CA180886 (50), 2019 (48), 2018 (43), 2016 (39), 2014 (35), P30CA033572 (32), 2009 (30), 2015 (27), 2017 (24), P30CA015083 (24), 2025 (23), P30CA008748 (23), P30CA016672 (23)